Literature DB >> 21974754

Implications of ambulatory blood pressure monitoring substudies on the interpretation of clinical trials in hypertension: should the threshold for drug therapy be lower in older patients?

Martin G Myers1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21974754      PMCID： PMC8108944          DOI： 10.1111/j.1751-7176.2011.00505.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  18 in total

1.  Rationale and methodology of monitoring ambulatory blood pressure and arterial compliance in the Hypertension in the Very Elderly Trial.

Authors:  Elisabete Pinto; Christopher Bulpitt; Nigel Beckett; Ruth Peters; Jan A Staessen; Chakravarthi Rajkumar
Journal:  Blood Press Monit       Date:  2006-02       Impact factor: 1.444

Review 2.  Measurement of blood pressure in the office: recognizing the problem and proposing the solution.

Authors:  Martin G Myers; Marshall Godwin; Martin Dawes; Alexander Kiss; Sheldon W Tobe; Janusz Kaczorowski
Journal:  Hypertension       Date:  2009-12-28       Impact factor: 10.190

3.  Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators.

Authors:  J A Staessen; L Thijs; R Fagard; E T O'Brien; D Clement; P W de Leeuw; G Mancia; C Nachev; P Palatini; G Parati; J Tuomilehto; J Webster
Journal:  JAMA       Date:  1999-08-11       Impact factor: 56.272

4.  Diagnosis of white coat hypertension by ambulatory blood pressure monitoring.

Authors:  P Owens; N Atkins; E O'Brien
Journal:  Hypertension       Date:  1999-08       Impact factor: 10.190

5.  How common is white coat hypertension?

Authors:  T G Pickering; G D James; C Boddie; G A Harshfield; S Blank; J H Laragh
Journal:  JAMA       Date:  1988-01-08       Impact factor: 56.272

6.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

Authors:  J A Staessen; R Fagard; L Thijs; H Celis; G G Arabidze; W H Birkenhäger; C J Bulpitt; P W de Leeuw; C T Dollery; A E Fletcher; F Forette; G Leonetti; C Nachev; E T O'Brien; J Rosenfeld; J L Rodicio; J Tuomilehto; A Zanchetti
Journal:  Lancet       Date:  1997-09-13       Impact factor: 79.321

7.  Is resistant hypertension really resistant?

Authors:  M A Brown; M L Buddle; A Martin
Journal:  Am J Hypertens       Date:  2001-12       Impact factor: 2.689

8.  White coat hypertension is a cardiovascular risk factor: a 10-year follow-up study.

Authors:  P H Gustavsen; A Høegholm; L E Bang; K S Kristensen
Journal:  J Hum Hypertens       Date:  2003-12       Impact factor: 3.012

9.  Treatment of hypertension in patients 80 years of age or older.

Authors:  Nigel S Beckett; Ruth Peters; Astrid E Fletcher; Jan A Staessen; Lisheng Liu; Dan Dumitrascu; Vassil Stoyanovsky; Riitta L Antikainen; Yuri Nikitin; Craig Anderson; Alli Belhani; Françoise Forette; Chakravarthi Rajkumar; Lutgarde Thijs; Winston Banya; Christopher J Bulpitt
Journal:  N Engl J Med       Date:  2008-03-31       Impact factor: 91.245

10.  Diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year cardiovascular risk.

Authors:  Masahiro Kikuya; Tine W Hansen; Lutgarde Thijs; Kristina Björklund-Bodegård; Tatiana Kuznetsova; Takayoshi Ohkubo; Tom Richart; Christian Torp-Pedersen; Lars Lind; Hans Ibsen; Yutaka Imai; Jan A Staessen
Journal:  Circulation       Date:  2007-04-09       Impact factor: 29.690
View more
  2 in total

Review 1.  Twenty-four-hour ambulatory blood pressure monitoring in hypertension: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2012-05-01

2.  A Canadian perspective on the Eighth Joint National Committee (JNC 8) hypertension guidelines.

Authors:  Martin G Myers; Sheldon W Tobe
Journal:  J Clin Hypertens (Greenwich)       Date:  2014-03-19       Impact factor: 3.738
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.